Annexin Pharmaceuticals AB (publ) (STO:ANNX)

Sweden · Delayed Price · Currency is SEK

6.26

-0.32 (-4.86%)

Nov 3, 2026, 5:29 PM CET

STO:ANNX Financials Overview

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Income	-42.01	-36.31	-50.4	-44.04	-40.66	-52.83
Net Income	-42.08	-36.89	-50.25	-44.05	-40.73	-52.14
Earnings Per Share	-5.67	-5.58	-11.11	-26.36	-27.84	-63.55
EPS Growth	-	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	14.44	27.4	16.34	21.42	31.11	49.48
Total Debt	-	-	-	-	-	-
Net Cash (Debt)	14.44	27.4	16.34	21.42	31.11	49.48
Net Cash Growth	-60.85%	67.69%	-23.71%	-31.17%	-37.12%	172.88%
Net Cash Per Share	1.95	4.14	3.61	12.82	21.27	60.31

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-41.22	-36.93	-50.23	-43.4	-41.17	-45.02
Capital Expenditures	-	-0.13	-	-	-	-
Free Cash Flow	-41.22	-37.05	-50.23	-43.4	-41.17	-45.02
Free Cash Flow Growth	-	-	-	-	-	-

Valuation

Selected indicators aren't available for this stock.